CiuffiA. (2008). Mechanisms governing lentivirus integration site
selection. Current Gene Therapy, 8(6), 419–429.
2.
EvansL., AlamgirA., OwensN., WeberN. & VirtanevaK. (2009). Mobilization of endogenous retroviruses in mice
after infection with an exogenous retrovirus. Journal of
Virology, 83(6), 2429–2435.
3.
GeukingM., WeberJ., DewannieuxM., GorelikE. & HeidmannT. (2009). Recombination of retrotransposon and exogenous RNA
virus results in nonretroviral cDNA integration. Science, 323(5912), 393–396.
4.
HackettC. & GeurtsA. & HackettP. (2007). Predicting preferential DNA vector insertion sites:
Implications for functional genomics and gene therapy. Genome
Biology, 8(Suppl 1), S12.1–S12.17.
5.
KatzourakisA. & PereiraV. & TristemM. (2007). Effects of recombination rate on human endogenous
retrovirus fixation and persistence. Journal of
Virology, 81(19), 10712–10717.
6.
LambertM.
S. (2007). Safety
advance: Transposon gene delivery systems. Applied Biosafety:
Journal of the American Biological Safety Association, 12(3), 196–197.
7.
LambertM.
S. (2008). A primer on
recombination and what it means to biological safety. Applied
Biosafety: Journal of the American Biological Safety Association, 13(3), 177–179.
MoyesD. & GriffithsD. & VenablesP. (2007). Insertional polymorphisms: A new lease of life for
endogenous retroviruses in human disease. Trends in
Genetics, 23(7), 326–333.
10.
NairV. (2008). Retrovirus-induced oncogenesis and safety of
retroviral vectors. Current Opinion in Molecular
Therapeutics, 10(5), 431–438.
